Korean J Gastroenterol.  2023 Nov;82(5):224-232. 10.4166/kjg.2023.108.

Hepatorenal Syndrome

• Choi JC
• Yoo JJ

• KMID: 2548492
• DOI: http://doi.org/10.4166/kjg.2023.108

Abstract

Hepatorenal syndrome (HRS) is a critical and potentially life-threatening complication of advanced liver disease, including cirrhosis. It is characterized by the development of renal dysfunction in the absence of underlying structural kidney pathology. The pathophysiology of HRS involves complex interactions between systemic and renal hemodynamics, neurohormonal imbalances, and the intricate role of vasoconstrictor substances. Understanding these mechanisms is crucial for the timely identification and management of HRS. The diagnosis of HRS is primarily clinical and relies on specific criteria that consider the exclusion of other causes of renal dysfunction. The management of HRS comprises two main approaches: vasoconstrictor therapy and albumin infusion, which aim to improve renal perfusion and mitigate the hyperdynamic circulation often seen in advanced liver disease. Additionally, strategies such as liver transplantation and renal replacement therapy are essential considerations based on individual patient characteristics and disease severity. This review article provides a comprehensive overview of hepatorenal syndrome, focusing on its pathophysiology, diagnostic criteria, and current management strategies.

Keyword

Hepatorenal syndrome; Liver cirrhosis; Acute kidney injury

Figure

• 

  Fig. 1 Pathophysiology of the hepatorenal syndrome. PAMPs, Pathogen-Associated Molecular Patterns; DAMPs, Damage-Associated Molecular Patterns; HRS-AKI, hepatorenal syndrome-acute kidney injury.

• 

  Fig. 2 Overview of the treatment for hepatorenal syndrome.

Reference

1. Fagundes C, Barreto R, Guevara M, et al. 2013; A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 59:474–481. DOI: 10.1016/j.jhep.2013.04.036. PMID: 23669284.

2. Piano S, Rosi S, Maresio G, et al. 2013; Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol. 59:482–489. DOI: 10.1016/j.jhep.2013.03.039. PMID: 23665185.

3. Sujan R, Cruz-Lemini M, Altamirano J, et al. 2018; A validated score predicts acute kidney injury and survival in patients with alcoholic hepatitis. Liver Transpl. 24:1655–1664. DOI: 10.1002/lt.25328. PMID: 30153377.

4. Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. 2013; Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 57:753–762. DOI: 10.1002/hep.25735. PMID: 22454364. PMCID: PMC3390443.

5. Huelin P, Piano S, Solà E, et al. 2017; Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure. Clin Gastroenterol Hepatol. 15:438–445.e5. DOI: 10.1016/j.cgh.2016.09.156. PMID: 27720915.

6. Allegretti AS, Ortiz G, Wenger J, et al. 2015; Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: A prospective cohort study. Int J Nephrol. 2015:108139. DOI: 10.1155/2015/108139. PMID: 26266048. PMCID: PMC4525763.

7. Ginès A, Escorsell A, Ginès P, et al. 1993; Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 105:229–236. DOI: 10.1016/0016-5085(93)90031-7. PMID: 8514039.

8. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. 2005; Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 42:439–447. DOI: 10.1002/hep.20766. PMID: 15977202.

9. Arroyo V, Guevara M, Ginès P. 2002; Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology. 122:1658–1676. DOI: 10.1053/gast.2002.33575. PMID: 12016430.

10. Alessandria C, Ozdogan O, Guevara M, et al. 2005; MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 41:1282–1289. DOI: 10.1002/hep.20687. PMID: 15834937.

11. Gilbertson EL, Krishnasamy R, Foote C, Kennard AL, Jardine MJ, Gray NA. 2019; Burden of care and quality of life among caregivers for adults receiving maintenance dialysis: A systematic review. Am J Kidney Dis. 73:332–343. DOI: 10.1053/j.ajkd.2018.09.006. PMID: 30454885.

12. Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G. 2019; The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ. 22:421–429. DOI: 10.1080/13696998.2019.1580201. PMID: 30724682.

13. Ginès P, Guevara M, Arroyo V, Rodés J. 2003; Hepatorenal syndrome. Lancet. 362:1819–1827. DOI: 10.1016/S0140-6736(03)14903-3. PMID: 14654322.

14. Wadei HM, Mai ML, Ahsan N, Gonwa TA. 2006; Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 1:1066–1079. DOI: 10.2215/CJN.01340406. PMID: 17699328.

15. Ginès P, Schrier RW. 2009; Renal failure in cirrhosis. N Engl J Med. 361:1279–1290. DOI: 10.1056/NEJMra0809139. PMID: 19776409.

16. Arroyo V, Ginès P, Gerbes AL, et al. 1996; Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 23:164–176. DOI: 10.1002/hep.510230122. PMID: 8550036.

17. Baldus WP, Feichter RN, Summerskill WH. 1964; The kidney in cirrhosis. I. Clinical and biochemical features of azotemia in hepatic failure. Ann Intern Med. 60:353–365. DOI: 10.7326/0003-4819-60-3-353. PMID: 14128217.

18. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. 2007; Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 52:742–748. DOI: 10.1007/s10620-006-9312-0. PMID: 17235705.

19. Angeli P, Ginès P, Wong F, et al. 2015; Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 62:968–974. DOI: 10.1016/j.jhep.2014.12.029. PMID: 25638527.

20. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. 2019; News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 71:811–822. DOI: 10.1016/j.jhep.2019.07.002. PMID: 31302175.

21. Piano S, Schmidt HH, Ariza X, et al. 2018; Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome. Clin Gastroenterol Hepatol. 16:1792–1800.e3. DOI: 10.1016/j.cgh.2018.01.035. PMID: 29391267.

22. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. 2011; Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 55:315–321. DOI: 10.1016/j.jhep.2010.11.020. PMID: 21167235. PMCID: PMC3728672.

23. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. 1988; Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 8:1151–1157. DOI: 10.1002/hep.1840080532. PMID: 2971015.

24. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. 1994; Hepatorenal disorders: role of the renin-angiotensin-aldosterone system. Semin Liver Dis. 14:23–34. DOI: 10.1055/s-2007-1007295. PMID: 8016659.

25. Thabut D, Massard J, Gangloff A, et al. 2007; Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 46:1872–1882. DOI: 10.1002/hep.21920. PMID: 17972337.

26. Sort P, Navasa M, Arroyo V, et al. 1999; Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 341:403–409. DOI: 10.1056/NEJM199908053410603. PMID: 10432325.

27. Barreto R, Fagundes C, Guevara M, et al. 2014; Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology. 59:1505–1513. DOI: 10.1002/hep.26687. PMID: 24037970.

28. Albillos A, Lario M, Álvarez-Mon M. 2014; Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 61:1385–1396. DOI: 10.1016/j.jhep.2014.08.010. PMID: 25135860.

29. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. 2015; Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 63:1272–1284. DOI: 10.1016/j.jhep.2015.07.004. PMID: 26192220.

30. Follo A, Llovet JM, Navasa M, et al. 1994; Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 20:1495–1501. DOI: 10.1002/hep.1840200619. PMID: 7982650.

31. Terra C, Guevara M, Torre A, et al. 2005; Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology. 129:1944–1953. DOI: 10.1053/j.gastro.2005.09.024. PMID: 16344063.

32. Fasolato S, Angeli P, Dallagnese L, et al. 2007; Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 45:223–229. DOI: 10.1002/hep.21443. PMID: 17187409.

33. Pereira G, Guevara M, Fagundes C, et al. 2012; Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol. 56:1040–1046. DOI: 10.1016/j.jhep.2011.11.023. PMID: 22245902.

34. Ariza X, Solà E, Elia C, et al. 2015; Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One. 10:e0128145. DOI: 10.1371/journal.pone.0128145. PMID: 26042740. PMCID: PMC4456079.

35. Garcia-Tsao G, Parikh CR, Viola A. 2008; Acute kidney injury in cirrhosis. Hepatology. 48:2064–2077. DOI: 10.1002/hep.22605. PMID: 19003880.

36. Alsaad AA, Wadei HM. 2016; Fractional excretion of sodium in hepatorenal syndrome: Clinical and pathological correlation. World J Hepatol. 8:1497–1501. DOI: 10.4254/wjh.v8.i34.1497. PMID: 28008340. PMCID: PMC5143430.

37. Carvounis CP, Nisar S, Guro-Razuman S. 2002; Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int. 62:2223–2229. DOI: 10.1046/j.1523-1755.2002.00683.x. PMID: 12427149.

38. Patidar KR, Kang L, Bajaj JS, Carl D, Sanyal AJ. 2018; Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis. Hepatology. 68:224–233. DOI: 10.1002/hep.29772. PMID: 29315697. PMCID: PMC6033653.

39. Francoz C, Nadim MK, Durand F. 2016; Kidney biomarkers in cirrhosis. J Hepatol. 65:809–824. DOI: 10.1016/j.jhep.2016.05.025. PMID: 27238754.

40. Allegretti AS, Solà E, Ginès P. 2020; Clinical application of kidney biomarkers in cirrhosis. Am J Kidney Dis. 76:710–719. DOI: 10.1053/j.ajkd.2020.03.016. PMID: 32622560.

41. Fagundes C, Pépin MN, Guevara M, et al. 2012; Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 57:267–273. DOI: 10.1016/j.jhep.2012.03.015. PMID: 22521351.

42. Verna EC, Brown RS, Farrand E, et al. 2012; Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci. 57:2362–2370. DOI: 10.1007/s10620-012-2180-x. PMID: 22562534. PMCID: PMC3979299.

43. Belcher JM, Sanyal AJ, Peixoto AJ, et al. 2014; Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 60:622–632. DOI: 10.1002/hep.26980. PMID: 24375576. PMCID: PMC4065642.

44. Huelin P, Solà E, Elia C, et al. 2019; Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: A prospective study. Hepatology. 70:319–333. DOI: 10.1002/hep.30592. PMID: 30810244.

45. Hamdy HS, El-Ray A, Salaheldin M, et al. 2018; Urinary neutrophil gelatinase-associated lipocalin in cirrhotic patients with acute kidney injury. Ann Hepatol. 17:624–630. DOI: 10.5604/01.3001.0012.0931. PMID: 29893703.

46. Barreto R, Elia C, Solà E, et al. 2014; Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol. 61:35–42. DOI: 10.1016/j.jhep.2014.02.023. PMID: 24613364.

47. Wong F, Jepsen P, Watson H, Vilstrup H. 2018; Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. Liver Int. 38:1785–1792. DOI: 10.1111/liv.13738. PMID: 29532591.

48. Angeli P, Morando F. 2010; Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepat Med. 2:87–98. DOI: 10.2147/HMER.S6918. PMID: 24367209. PMCID: PMC3846372.

49. Caraceni P, Riggio O, Angeli P, et al. 2018; Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 391:2417–2429. DOI: 10.1016/S0140-6736(18)30840-7. PMID: 29861076.

50. Fernández J, Navasa M, Planas R, et al. 2007; Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 133:818–824. DOI: 10.1053/j.gastro.2007.06.065. PMID: 17854593.

51. Kamal F, Khan MA, Khan Z, et al. 2017; Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 29:1109–1117. DOI: 10.1097/MEG.0000000000000940. PMID: 28763340.

52. Ginès P, Titó L, Arroyo V, et al. 1988; Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 94:1493–1502. DOI: 10.1016/0016-5085(88)90691-9. PMID: 3360270.

53. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. 2012; Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 55:1172–1181. DOI: 10.1002/hep.24786. PMID: 22095893.

54. Martín-Llahí M, Pépin MN, Guevara M, et al. 2008; Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 134:1352–1359. DOI: 10.1053/j.gastro.2008.02.024. PMID: 18471512.

55. Wong F, Pappas SC, Boyer TD, et al. 2017; Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome. Clin Gastroenterol Hepatol. 15:266–272.e1. DOI: 10.1016/j.cgh.2016.07.016. PMID: 27464593.

56. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. 2008; A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 134:1360–1368. DOI: 10.1053/j.gastro.2008.02.014. PMID: 18471513. PMCID: PMC3730280.

57. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. 2007; Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 47:499–505. DOI: 10.1016/j.jhep.2007.04.010. PMID: 17560680.

58. Cavallin M, Kamath PS, Merli M, et al. 2015; Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 62:567–574. DOI: 10.1002/hep.27709. PMID: 25644760.

59. Ortega R, Ginès P, Uriz J, et al. 2002; Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 36:941–948. DOI: 10.1053/jhep.2002.35819. PMID: 12297842.

60. Ibrahim ES, Alsebaey A, Zaghla H, Moawad Abdelmageed S, Gameel K, Abdelsameea E. 2017; Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. Eur J Gastroenterol Hepatol. 29:1247–1250. DOI: 10.1097/MEG.0000000000000967. PMID: 28902040.

61. Dong T, Aronsohn A, Gautham Reddy K, Te HS. 2016; Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis. Dig Dis Sci. 61:3621–3626. DOI: 10.1007/s10620-016-4313-0. PMID: 27655104.

62. Zhang WJ, Frei B. 2002; Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res. 55:820–829. DOI: 10.1016/S0008-6363(02)00492-3. PMID: 12176131.

63. Bortoluzzi A, Ceolotto G, Gola E, et al. 2013; Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology. 57:266–276. DOI: 10.1002/hep.26021. PMID: 22911662.

64. Stocker R, Glazer AN, Ames BN. 1987; Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A. 84:5918–5922. DOI: 10.1073/pnas.84.16.5918. PMID: 3475708. PMCID: PMC298974.

65. Cantin AM, Paquette B, Richter M, Larivée P. 2000; Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation. Am J Respir Crit Care Med. 162:1539–1546. DOI: 10.1164/ajrccm.162.4.9910106. PMID: 11029374.

66. Lejon S, Frick IM, Björck L, Wikström M, Svensson S. 2004; Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin. J Biol Chem. 279:42924–42928. DOI: 10.1074/jbc.M406957200. PMID: 15269208.

67. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. 2003; Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 18:152–156. DOI: 10.1046/j.1440-1746.2003.02934.x. PMID: 12542598.

68. Neri S, Pulvirenti D, Malaguarnera M, et al. 2008; Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 53:830–835. DOI: 10.1007/s10620-007-9919-9. PMID: 17939047.

69. Boyer TD, Sanyal AJ, Wong F, et al. 2016; Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 150:1579–1589.e2.

70. Sharma P, Kumar A, Shrama BC, Sarin SK. 2008; An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 103:1689–1697. DOI: 10.1111/j.1572-0241.2008.01828.x. PMID: 18557715.

71. Singh V, Ghosh S, Singh B, et al. 2012; Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 56:1293–1298. DOI: 10.1016/j.jhep.2012.01.012. PMID: 22322237.

72. Arora V, Maiwall R, Rajan V, et al. 2020; Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 71:600–610. DOI: 10.1002/hep.30208. PMID: 30076614.

73. Jamil K, Pappas SC, Devarakonda KR. 2017; In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2. J Exp Pharmacol. 10:1–7. DOI: 10.2147/JEP.S146034. PMID: 29302194. PMCID: PMC5741980.

74. Russell JA, Walley KR. 2010; Vasopressin and its immune effects in septic shock. J Innate Immun. 2:446–460. DOI: 10.1159/000318531. PMID: 20606409.

75. Sanyal AJ, Boyer TD, Frederick RT, et al. 2017; Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 45:1390–1402. DOI: 10.1111/apt.14052. PMID: 28370090. PMCID: PMC5434950.

76. Nazar A, Pereira GH, Guevara M, et al. 2010; Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 51:219–226. DOI: 10.1002/hep.23283. PMID: 19877168.

77. Simonetto DA, Gines P, Kamath PS. 2020; Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 370:m2687. DOI: 10.1136/bmj.m2687. PMID: 32928750.

78. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. 2003; Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 38:238–243. DOI: 10.1053/jhep.2003.50276. PMID: 12830007.

79. Runyon BA. AASLD Practice Guidelines Committee. 2009; Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 49:2087–2107. DOI: 10.1002/hep.22853. PMID: 19475696.

80. El-Desoki Mahmoud EI, Abdelaziz DH, Abd-Elsalam S, Mansour NO. 2021; Norepinephrine is more effective than midodrine/octreotide in patients with hepatorenal syndrome-acute kidney injury: A randomized controlled trial. Front Pharmacol. 12:675948. DOI: 10.3389/fphar.2021.675948. PMID: 34276366. PMCID: PMC8283260.

81. Facciorusso A, Chandar AK, Murad MH, et al. 2017; Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2:94–102. DOI: 10.1016/S2468-1253(16)30157-1. PMID: 28403995.

82. Zhang Z, Maddukuri G, Jaipaul N, Cai CX. 2015; Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. J Crit Care. 30:969–974. DOI: 10.1016/j.jcrc.2015.05.006. PMID: 26051980.

83. Lenhart A, Hussain S, Salgia R. 2018; Chances of renal recovery or liver transplantation after hospitalization for alcoholic liver disease requiring dialysis. Dig Dis Sci. 63:2800–2809. DOI: 10.1007/s10620-018-5170-9. PMID: 29934721.

84. Israni AK, Xiong H, Liu J, et al. 2013; Predicting end-stage renal disease after liver transplant. Am J Transplant. 13:1782–1792. DOI: 10.1111/ajt.12257. PMID: 23668976.

85. Chauhan K, Azzi Y, Faddoul G, et al. 2018; Pre-liver transplant renal dysfunction and association with post-transplant end-stage renal disease: A single-center examination of updated UNOS recommendations. Clin Transplant. 32:e13428. DOI: 10.1111/ctr.13428. PMID: 30338873.

86. Bera C, Wong F. 2022; Management of hepatorenal syndrome in liver cirrhosis: a recent update. Therap Adv Gastroenterol. 15:17562848221102679. DOI: 10.1177/17562848221102679. PMID: 35721838. PMCID: PMC9201357.